Revolution Medicines is a pioneering biotech firm focused on creating innovative treatments for cancers driven by RAS mutations. With a robust pipeline of novel targeted therapies, the company is at the forefront of precision oncology. Its leading candidates, including RMC-6236, RMC-6291, and RMC-9805, are undergoing clinical trials to tackle various RAS-addicted cancers. Additionally, Revolution Medicines is exploring combination treatments to enhance efficacy. Founded in 2014 and based in Redwood City, California, the company is dedicated to transforming cancer treatment paradigms.
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math…
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Live Updates Nike Was Downgraded Again8:30am ETWall Street has apparently lost its patience with Nike. After pushing recovery hopes out a bit further with its last batch of earnings, analysts at HSBC…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Wednesday's top analyst upgrades and downgrades included Broadcom, Clean Energy Fuels, Dish Network, First Republic Bank, Gaming and Leisure Properties, Occidental Petroleum, Revolution Medicines, Veeva Systems and Workday.
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
Monday's top analyst upgrades, downgrades and initiations included American Express, ADT, Gilead Sciences, Logitech, PACCAR, Regions Financial, Stamps.com and Vivint Smart Home.
